Clinical Trials
2 trialsNCT02289209 2025-03-06
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
University of Pittsburgh
Phase 2 Completed
NCT03661723 2024-09-19
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed